10/13/2020 7:01:34 AM
CTI BioPharma Initiates Rolling Submission Of NDA For Pacritinib In Myelofibrosis Patients With Severe Thrombocytopenia
8/6/2020 4:25:15 PM
CTI BioPharma Q2 Loss/Shr $0.19, Same As Last Year
6/1/2020 7:02:42 AM
CTI BioPharma Enrolls 1st Patient In Phase 3 PRE-VENT Trial Of Pacritinib In Hospitalized Patients With Severe COVID-19
5/7/2020 4:16:42 PM
CTI BioPharma Q1 Loss/share $0.20 Vs. Loss $0.19 Year Ago
4/27/2020 7:02:08 AM
CTI BioPharma Initiates PRE-VENT Phase 3 Study Evaluating Pacritinib In Hospitalized Patients With Severe COVID-19
3/12/2020 4:06:51 PM
CTI BioPharma Q4 Loss/share $0.14 Vs. Profit $0.01 Year Ago
2/14/2020 7:04:52 AM
CTI BioPharma Commences Rights Offering To Raise Gross Proceeds Of About $60.0 Mln